GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quince Therapeutics Inc (NAS:QNCX) » Definitions » Equity-to-Asset

Quince Therapeutics (Quince Therapeutics) Equity-to-Asset : 0.51 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Quince Therapeutics Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Quince Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $85.08 Mil. Quince Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $167.90 Mil.

The historical rank and industry rank for Quince Therapeutics's Equity-to-Asset or its related term are showing as below:

QNCX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.63   Med: 0.89   Max: 0.97
Current: 0.51

During the past 7 years, the highest Equity to Asset Ratio of Quince Therapeutics was 0.97. The lowest was -2.63. And the median was 0.89.

QNCX's Equity-to-Asset is ranked worse than
63.71% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs QNCX: 0.51

Quince Therapeutics Equity-to-Asset Historical Data

The historical data trend for Quince Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quince Therapeutics Equity-to-Asset Chart

Quince Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial 0.93 0.91 0.89 0.97 0.51

Quince Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.97 0.98 0.97 0.51

Competitive Comparison of Quince Therapeutics's Equity-to-Asset

For the Biotechnology subindustry, Quince Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quince Therapeutics's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Equity-to-Asset falls into.



Quince Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Quince Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=85.084/167.9
=

Quince Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=85.084/167.9
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quince Therapeutics  (NAS:QNCX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Quince Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Quince Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Quince Therapeutics (Quince Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
601 Gateway Boulevard, Suite 1250, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.
Executives
David Lamond director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Guenter Janhofer officer: Chief Scientific Officer 601 GATEWAY BOULEVARD, SUITE 1250, SOUTH SAN FRANCISCO CA 94080
Luca Benatti director C/O INTERCEPT PHARMACEUTICALS, INC., 450 WEST 15TH STREET, SUITE 505, NEW YORK NY 10011
Charles S. Ryan officer: President C/O APPLIED DNA SCIENCES, INC., 50 HEALTH SCIENCES DRIVE, STONY BROOK NY 11790
Dirk Thye director, officer: Chief Executive Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Brendan Hannah officer: Chief Business Officer 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Margaret Mcloughlin director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Ted Monohon officer: Chief Accounting Officer C/O FANTEX, INC., 330 TOWNSEND ST., SUITE 234, SAN FRANCISCO CA 94107
June Bray director C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Caryn Gordon Mcdowell officer: Chief Legal & Adm. Officer 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Karen L. Smith officer: Chief Medical Officer C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Philip S Low director 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Marwan Sabbagh director C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Stephen S. Dominy director, officer: Chief Scientific Officer C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94105
Christopher P. Lowe officer: Chief Financial Officer 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258